Datasets:
hackint0sh
/
Text-Clinical-Records

Dataset card Data Studio Files Community
text
stringlengths
0
197k
<|newrecord|> nctId: NCT06262048 id: PrePOURTS briefTitle: Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial acronym: PrePOURTS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-30 date: 2025-05-31 date: 2024-02-15 date: 2024-02-15 name: Lawson Health Research Institute class: OTHER briefSummary: The objectives of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and improving other clinical outcomes in people undergoing pulmonary surgery. conditions: Urinary Retention Postoperative studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: single centre, double blind randomized controlled trial primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 64 type: ESTIMATED name: Tamsulosin Hydrochloride name: Placebo measure: Rate of post operative urinary retention measure: Rate of Straight Catheterizations measure: Rate of Indwelling Catheterizations measure: Time to first catheterization measure: Treatment Related Adverse Events measure: Catheter related complications measure: Length of stay sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: London Health Sciences Centre city: London state: Ontario zip: N6A 5W9 country: Canada lat: 42.98339 lon: -81.23304 hasResults: False
<|newrecord|> nctId: NCT06262035 id: 2023-02987-01 briefTitle: Transcriptome, Proteome and Microbiome Profile in Periodontal and Peri-implant Diseases overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2028-12-31 date: 2030-12-31 date: 2024-02-15 date: 2024-02-15 name: Karolinska Institutet class: OTHER briefSummary: 1. To investigate the transcriptomic profile of periodontitis and peri-implantitis. Patients with defined periodontitis, at two non-adjacent teeth and peri-implantitis at ≥ one implant in function of ≥ one year, will be included to investigate the gene expression profile in tissue affected by periodontitis and peri-implantitis. Subjects will undergo a full-mouth examination performed by a calibrated examiner, including assessment of caries, bone abnormalities and infections according to intraoral x-ray, plaque index and pocket probing depth, suppuration, bleeding on probing, alveolar bone loss, and the number of teeth. During surgical intervention, tissue biopsies (two specimens per site) will be collected by a periodontist from site with ongoing periodontitis and site from ongoing peri-implantitis.
2. To study the microbiome and biomarker profile associated with periodontitis and peri- implantitis. Patients with defined periodontitis, at two non-adjacent teeth and peri-implantitis at ≥ one implant in function of ≥ one year, will be included in this study to determine the bacteria composition, cytokine profile and inflammatory biomarkers profile. Subjects will undergo a full-mouth examination performed by a calibrated examiner, including assessment of caries, bone abnormalities and infections according to intraoral x-ray, plaque index and pocket probing depth, suppuration, bleeding on probing, alveolar bone loss, and number of teeth. Peri-implant crevicular fluid (PICF), gingival crevicular fluid (GCF), saliva and submucosal/subgingival plaque will be collected.The presence and composition of periodontal and peri-implant plaque samples are investigated. conditions: Peri-implantitis conditions: Periodontitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED name: Periodontitis and Peri-implantitis measure: Protein levels in peri-implantitis and periodontitis measure: Microbiome composition in peri-implantitis and periodontitis using 16S-rRNA sequencing method. measure: Gene expression profile in peri-implantitis and periodontitis. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06262022 id: KaramanogluMehmetbeyUFGok briefTitle: The Effect of Cold Application on Pain Level, Edema and Drainage Amount overallStatus: RECRUITING date: 2024-01-15 date: 2024-04-30 date: 2024-04-30 date: 2024-02-15 date: 2024-02-15 name: Karamanoğlu Mehmetbey University class: OTHER name: Karaman Training and Research Hospital briefSummary: In this study, we aimed to investigate the effect of cold application applied for 20 minutes every hour for 8 hours on the first day, second and third days after total hip arthroplasty with gel pads, on the pain level, edema and drainage amount of total hip arthroplasty patients. The main question\[s\]it aims to answer are:
* Is there a difference between the pain levels of patients in the control and cold application arms?
* Is there a difference between the knee edema of patients in the control and cold application arms?
* Is there a difference between the amount of drainage of patients in the control and cold application arms? This study was planned as a prospective, parallel, two-arm (1:1) randomized controlled trial (RCT). conditions: Cold Therapy conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study was planned as a prospective, parallel, two-arm (1:1) randomized controlled trial (RCT). primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 78 type: ESTIMATED name: cold therapy measure: pain level measure: edema measure: amount of drainage measure: Analgesic consumption sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karamanoğlu Mehmet bey Üniversitesi status: RECRUITING city: Merkez state: Karaman zip: 70100 country: Turkey name: fatma gök role: CONTACT phone: 05544906142 email: fatmagok123@gmail.com hasResults: False
<|newrecord|> nctId: NCT06262009 id: APHP220101 id: 2023-A02282-43 type: OTHER domain: IDRCB briefTitle: Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment acronym: Dyaspeo overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2027-03 date: 2024-02-15 date: 2024-02-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO conditions: Antibiotic Resistant Strain conditions: Transmission, Close-Contact studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 525 type: ESTIMATED name: human faecal collection name: ancillary study measure: generation of a list of priorities for future prevention and control strategies to mitigate antimicrobial resistance (AMR) transmission between companion animals and humans measure: Rates of AMR acquisitions in one or several housekeepers measure: A list in nature of changes in dog microbiota measure: A list in magnitude of changes in dog microbiota measure: A list in nature of changes in housekeepers microbiota measure: A list in magnitude of changes in housekeepers microbiota measure: explore unknown parameters of AMR colonization in dogs under various antibiotic exposures measure: the generation of a list of sociological factors and potential at-risk practices relevant in the transmission of AMR from dogs to housekeepers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: the National Veterinary School Alfort city: Maisons-Alfort zip: 94700 country: France name: Jean-Yves Madec, PHD role: CONTACT phone: 06 85 08 93 30 phoneExt: +33 email: jean-yves.madec@anses.fr lat: 48.81171 lon: 2.43945 hasResults: False
<|newrecord|> nctId: NCT06261996 id: henanFSH briefTitle: Safety and Efficacy of Fospropofol vs Propofol During Invasive Mechanical Ventilation. overallStatus: NOT_YET_RECRUITING date: 2024-02-12 date: 2025-01-15 date: 2025-01-15 date: 2024-02-15 date: 2024-02-15 name: Henan Provincial People's Hospital class: OTHER briefSummary: The goal of this clinical trial is to compare the safety and efficacy of fospropofol and propofol during sedation in invasively mechanically ventilated patients in the Anesthesia Intensive Care Unit (AICU). Specific objectives include the following:
* Evaluate the sedative effects of fospropofol and propofol in invasively mechanically ventilated patients. Compare the sedative effects of the two medications using relevant clinical indicators and scoring tools, such as the Richmond Agitation-Sedation Scale (RASS).
* Compare the safety of fospropofol and propofol during sedation. Monitor medication-related adverse reactions, such as respiratory depression, hypotension, arrhythmias, headache, injection site pain, and assess the differences in adverse reaction incidence between the two medications.
* Compare the characteristics of recovery from sedation between PPD and propofol. Focus on the time from sedation to emergence from sedation and compare the differences in recovery time between the two medications.
Participants will be sedated with fospropofol or propofol during invasive mechanical ventilation. conditions: Invasive Mechanical Ventilation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Fospropofol measure: The patient's Richmond Agitation-Sedation Scale (RASS) score and the incidence of adverse reactions measure: Incidence of adverse reactions during the follow-up period measure: Extubation time sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06261983 id: 2019111032 briefTitle: Magnetic Localization of Sentinel Nodes in Squamous Cell Oral Carcinoma. acronym: SentiMag overallStatus: RECRUITING date: 2018-10-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: Hospital Donostia class: OTHER briefSummary: Sentinel node biopsy has been shown to be a viable alternative to elective neck dissection in the early stages of squamous cell oral carcinoma. The aim of this study was to describe the magnetic localization of sentinel nodes (SN) after peritumoral injection of superparamagnetic iron oxide (SPIO) for treating this type of tumor and to analyze the technique's diagnostic performance in 23 patients. The technique located SNs (with minimal complication) in 95.6 % (22/23) of the patients. Three relapses occurred, one in a patient who had shown negative in magnetic SN location and elective neck dissection. The diagnostic performance of magnetic localization achieved a sensitivity and negative predictive value of 0.80 y 0.94, respectively. Magnetic localization of SNs has been shown to be a reproducible technique that may offer a viable alternative to the conventional technique. conditions: Diagnostic Value of Sentinel Node Biopsy Guided by Magnetic Probe studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 24 type: ESTIMATED name: Sentinel node biopsy guided by magnetic probe measure: The diagnostic performance of SNB was analyzed in terms of sensitivity (S), specificity (Sp), negative and positive predictive value (NPV and PPV). sex: ALL minimumAge: 29 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Josué Hernando Vázquez status: RECRUITING city: Donostia state: Guipuzkoa zip: 20011 country: Spain name: Josué Hernando, PhD, DDS role: CONTACT phone: 0034 675825482 email: josue.hernando@gmail.com lat: 43.31283 lon: -1.97499 hasResults: False
<|newrecord|> nctId: NCT06261970 id: 999002684 briefTitle: Increase First-time Mothers' Use of Postpartum Family Planning in Tanzania: The Connect Project acronym: Connect TZ overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-22 date: 2024-12 date: 2025-12 date: 2024-02-15 date: 2024-02-20 name: George Washington University class: OTHER name: Save the Children name: Save the Children International Tanzania name: Bill and Melinda Gates Foundation briefSummary: While a growing body of programs have shown promise to increase use of contraception among first time mothers (FTMs), difficulties remain in scaling beyond small pilot areas and institutionalizing within existing systems. Connect's approach aims to strengthen existing government health systems and community-level health efforts, including those supported through local and international non-governmental organizations, by developing and testing light-touch "enhancements" with the goal of increasing postpartum Family Planning (PPFP) adoption among FTMs. The investigators will evaluate Connect's approach through a cluster randomized control trial. conditions: Contraceptive Usage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 1134 type: ACTUAL name: Connect measure: Adoption of of Postpartum Family Planning (PPFP): measure: Currently Using PPFP measure: Adopted or Intention to adopt PPFP measure: Average Satisfaction with PPFP methods measure: Contraceptive Preferences measure: Quality of Family Planning Counseling measure: Communication and Agency measure: PPFP Attitudes measure: PPFP Knowledge sex: FEMALE minimumAge: 14 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: EDI city: Bahi state: Dodoma country: Tanzania lat: -5.98304 lon: 35.3159 facility: EDI city: Kongwa state: Dodoma country: Tanzania lat: -6.2 lon: 36.41667 hasResults: False
<|newrecord|> nctId: NCT06261957 id: 220735 id: 2023-509001-76-00 type: OTHER domain: EU CT Number briefTitle: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma overallStatus: NOT_YET_RECRUITING date: 2024-04-19 date: 2025-04-25 date: 2025-04-25 date: 2024-02-15 date: 2024-02-15 name: GlaxoSmithKline class: INDUSTRY briefSummary: The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma. conditions: Asthma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 420 type: ESTIMATED name: Salbutamol HFA-134a name: Salbutamol HFA-152a measure: Number of participants with Adverse Events (AEs) measure: Number of participants with Serious Adverse Events (SAEs) measure: Absolute Values of Minimum serum potassium (milliequivalents per litre (mEq/L) measure: Absolute values of serum potassium (milligrams per decilitre) measure: Change from baseline in serum potassium (milligrams per decilitre) measure: Absolute value of haematology parameter: Platelet count (cells per microliter) measure: Absolute value of haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter) measure: Absolute value of haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters) measure: Absolute value of haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms) measure: Absolute values of haematology parameters: Reticulocytes (Percentage of reticulocytes) measure: Absolute values of haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre) measure: Absolute values of haematology parameters: haemoglobin (Hgb) (grams per decilitre) measure: Absolute values of haematology parameters: haematocrit (Proportion of red blood cells in blood) measure: Absolute values of Clinical Chemistry parameters: Glucose (non-fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre) measure: Absolute values of Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase,Alanine aminotransferase/serum glutamic-pyruvic transaminase, Alanine aminotransferase,Creatine phosphokinase (International Units per litre) measure: Absolute value of routine urinalysis: potential of hydrogen (pH) measure: Number of participants with abnormal urinalysis dipstick results: glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase measure: Change from baseline in haematology parameter: Platelet count (cells per microliter) measure: Change from baseline in haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter) measure: Change from baseline in haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters) measure: Change from baseline in haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms) measure: Change from baseline in haematology parameters: Reticulocytes (Percentage of reticulocytes) measure: Change from baseline in haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre) measure: Change from baseline in haematology parameters: haemoglobin (Hgb) (grams per decilitre) measure: Change from baseline in haematology parameters: haematocrit (Proportion of red blood cells in blood) measure: Change from baseline in Clinical Chemistry parameters: Glucose (non-fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre) measure: Change from baseline in Aspartate aminotransferase/ serum glutamic-oxaloacetic transaminase,Alanine aminotransferase/serum glutamic-pyruvic transaminase, Alanine aminotransferase,Creatine phosphokinase (International Units per litre) measure: Change from baseline in routine urinalysis: pH measure: Absolute values for vital signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [millimeters of mercury (mm Hg) measure: Absolute values for vital signs: pulse rate [beats per min (bpm) measure: Change from baseline in vital signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [millimeters of mercury (mm Hg) measure: Change from baseline in vital signs: pulse rate [beats per min (bpm) measure: Absolute values for 12 Lead ECGs in QTc (milliseconds) measure: Absolute values for heart rate [beats per min (bpm) measure: Change from baseline for 12 Lead ECGs in QTc (milliseconds) measure: Change from baseline for heart rate [beats per min (bpm) sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: GSK Investigational Site city: Aventura state: Florida zip: 33180 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Jaime Landman role: PRINCIPAL_INVESTIGATOR lat: 25.95648 lon: -80.13921 facility: GSK Investigational Site city: Clearwater state: Florida zip: 33756 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Miguel E Trevino role: PRINCIPAL_INVESTIGATOR lat: 27.96585 lon: -82.8001 facility: GSK Investigational Site city: Edgewater state: Florida zip: 32132 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Andrew C Feldman role: PRINCIPAL_INVESTIGATOR lat: 28.98888 lon: -80.90228 facility: GSK Investigational Site city: Miami state: Florida zip: 33155 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Eduardo Martinez role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 facility: GSK Investigational Site city: Winter Park state: Florida zip: 32789 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Akinyemi Ajayi role: PRINCIPAL_INVESTIGATOR lat: 28.6 lon: -81.33924 facility: GSK Investigational Site city: Rincon state: Georgia zip: 31326 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Maria Mascolo role: PRINCIPAL_INVESTIGATOR lat: 32.29603 lon: -81.23539 facility: GSK Investigational Site city: Louisville state: Kentucky zip: 40217 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: James Wesley Sublett role: PRINCIPAL_INVESTIGATOR lat: 38.25424 lon: -85.75941 facility: GSK Investigational Site city: Owensboro state: Kentucky zip: 42301 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Lee S Clore role: PRINCIPAL_INVESTIGATOR lat: 37.77422 lon: -87.11333 facility: GSK Investigational Site city: Minneapolis state: Minnesota zip: 55402 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Gary D Berman role: PRINCIPAL_INVESTIGATOR lat: 44.97997 lon: -93.26384 facility: GSK Investigational Site city: Olive Branch state: Mississippi zip: 38654 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Randall T. Huling role: PRINCIPAL_INVESTIGATOR lat: 34.96176 lon: -89.82953 facility: GSK Investigational Site city: Columbia state: Missouri zip: 65203 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Mark L Vandewalker role: PRINCIPAL_INVESTIGATOR lat: 38.95171 lon: -92.33407 facility: GSK Investigational Site city: Jersey City state: New Jersey zip: 07306 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Asisat Ope role: PRINCIPAL_INVESTIGATOR lat: 40.72816 lon: -74.07764 facility: GSK Investigational Site city: Riverdale state: New Jersey zip: 07457 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Jeffrey Weiss role: PRINCIPAL_INVESTIGATOR lat: 40.99399 lon: -74.30348 facility: GSK Investigational Site city: Brooklyn state: New York zip: 11220 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Ramsey Joudeh role: PRINCIPAL_INVESTIGATOR lat: 40.6501 lon: -73.94958 facility: GSK Investigational Site city: Asheville state: North Carolina zip: 28803 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: David Cypcar role: PRINCIPAL_INVESTIGATOR lat: 35.60095 lon: -82.55402 facility: GSK Investigational Site city: Cincinnati state: Ohio zip: 45231 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: David I Bernstein role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 facility: GSK Investigational Site city: Dublin state: Ohio zip: 43016 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Roy Carl St. John role: PRINCIPAL_INVESTIGATOR lat: 40.09923 lon: -83.11408 facility: GSK Investigational Site city: Medford state: Oregon zip: 97504 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Sarah Smiley role: PRINCIPAL_INVESTIGATOR lat: 42.32652 lon: -122.87559 facility: GSK Investigational Site city: DuBois state: Pennsylvania zip: 15801 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Sandeep Bansal role: PRINCIPAL_INVESTIGATOR lat: 41.11923 lon: -78.76003 facility: GSK Investigational Site city: Philadelphia state: Pennsylvania zip: 19107 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: David A Wheeler role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 facility: GSK Investigational Site city: Pittsburgh state: Pennsylvania zip: 15241 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Michael J. Palumbo role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 facility: GSK Investigational Site city: Greenville state: South Carolina zip: 29615 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Luis Ignacio De La Cruz role: PRINCIPAL_INVESTIGATOR lat: 34.85262 lon: -82.39401 facility: GSK Investigational Site city: Rock Hill state: South Carolina zip: 29732 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Michael Denenberg role: PRINCIPAL_INVESTIGATOR lat: 34.92487 lon: -81.02508 facility: GSK Investigational Site city: Spartanburg state: South Carolina zip: 29303 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Charles M. Fogarty role: PRINCIPAL_INVESTIGATOR lat: 34.94957 lon: -81.93205 facility: GSK Investigational Site city: Union state: South Carolina zip: 29379 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Joseph A Boscia III role: PRINCIPAL_INVESTIGATOR lat: 34.71541 lon: -81.62371 facility: GSK Investigational Site city: Burleson state: Texas zip: 76028 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Tiffany Baird role: PRINCIPAL_INVESTIGATOR lat: 32.54208 lon: -97.32085 facility: GSK Investigational Site city: Tomball state: Texas zip: 77375 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Mustafa Naeem role: PRINCIPAL_INVESTIGATOR lat: 30.09716 lon: -95.61605 facility: GSK Investigational Site city: Waco state: Texas zip: 76712 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Niran J. Amar role: PRINCIPAL_INVESTIGATOR lat: 31.54933 lon: -97.14667 facility: GSK Investigational Site city: Bellingham state: Washington zip: 98225 country: United States name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: David Elkayam role: PRINCIPAL_INVESTIGATOR lat: 48.75955 lon: -122.48822 facility: GSK Investigational Site city: Caba state: Buenos Aires zip: C1425BEN country: Argentina name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Anahi Yanez role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: GSK Investigational Site city: Ciudad de Buenos Aires zip: C1425AZE country: Argentina name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Nicolas Itcovici role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: GSK Investigational Site city: Mendoza zip: M5500CCG country: Argentina name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Pedro Carlos Elias role: PRINCIPAL_INVESTIGATOR lat: -32.89084 lon: -68.82717 facility: GSK Investigational Site city: Ajax state: Ontario zip: L1S 2J5 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: George Philteos role: PRINCIPAL_INVESTIGATOR lat: 43.85012 lon: -79.03288 facility: GSK Investigational Site city: Brampton state: Ontario zip: L6T 0G1 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Naresh K. Aggarwal role: PRINCIPAL_INVESTIGATOR lat: 43.68341 lon: -79.76633 facility: GSK Investigational Site city: Ottawa state: Ontario zip: K1H 1E4 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: William Yang role: PRINCIPAL_INVESTIGATOR lat: 45.41117 lon: -75.69812 facility: GSK Investigational Site city: Toronto state: Ontario zip: M9V 4B4 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Anil Gupta role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: GSK Investigational Site city: Windsor state: Ontario zip: N8X 2G1 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Joel Liem role: PRINCIPAL_INVESTIGATOR lat: 42.30008 lon: -83.01654 facility: GSK Investigational Site city: Quebec zip: G1V 4W2 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Remi Gagnon role: PRINCIPAL_INVESTIGATOR lat: 46.81228 lon: -71.21454 facility: GSK Investigational Site city: Quebec zip: G1W 4R4 country: Canada name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Catherine Vaillancourt role: PRINCIPAL_INVESTIGATOR lat: 46.81228 lon: -71.21454 facility: GSK Investigational Site city: Amiens Cedex 1 zip: 80054 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Sandrine Soriot-Thomas role: PRINCIPAL_INVESTIGATOR lat: 49.9 lon: 2.3 facility: GSK Investigational Site city: Argenteuil zip: 95100 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Vincent Ioos role: PRINCIPAL_INVESTIGATOR lat: 48.95 lon: 2.25 facility: GSK Investigational Site city: Brest cedex zip: 29609 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Pierrick Cros role: PRINCIPAL_INVESTIGATOR lat: 48.3903 lon: -4.48628 facility: GSK Investigational Site city: Cannes Cedex zip: 06614 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Fabien Rolland role: PRINCIPAL_INVESTIGATOR lat: 43.55135 lon: 7.01275 facility: GSK Investigational Site city: Créteil Cedex zip: 94010 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Ralph Epaud role: PRINCIPAL_INVESTIGATOR lat: 48.78333 lon: 2.46667 facility: GSK Investigational Site city: Libourne Cedex zip: 33505 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Laurent Portel role: PRINCIPAL_INVESTIGATOR lat: 44.91667 lon: -0.23333 facility: GSK Investigational Site city: Lille zip: 59000 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Caroline Thumerelle role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: GSK Investigational Site city: Poitiers cedex zip: 86021 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Etienne-Marie Jutant role: PRINCIPAL_INVESTIGATOR lat: 46.58333 lon: 0.33333 facility: GSK Investigational Site city: Pontoise zip: 95303 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Jean-François Boitiaux role: PRINCIPAL_INVESTIGATOR lat: 49.05 lon: 2.1 facility: GSK Investigational Site city: Strasbourg Cedex zip: 67091 country: France name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Naji Khayath role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 facility: GSK Investigational Site city: Larissa state: Thessaly zip: 41110 country: Greece name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Konstantinos Gourgoulianis role: PRINCIPAL_INVESTIGATOR lat: 39.63689 lon: 22.41761 facility: GSK Investigational Site city: Alexandroupolis zip: 68100 country: Greece name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Paschalis Steiropoulos role: PRINCIPAL_INVESTIGATOR lat: 40.84995 lon: 25.87644 facility: GSK Investigational Site city: Athina zip: 11527 country: Greece name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Paraskevi Xepapadaki role: PRINCIPAL_INVESTIGATOR facility: GSK Investigational Site city: Heraklion, Crete zip: 71500 country: Greece name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Emmanouil Paraskakis role: PRINCIPAL_INVESTIGATOR facility: GSK Investigational Site city: Thessaloniki zip: 57010 country: Greece name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Konstantinos Porpodis role: PRINCIPAL_INVESTIGATOR lat: 40.64361 lon: 22.93086 facility: GSK Investigational Site city: Monserrato state: Cagliari zip: 09042 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Stefano Del Giacco role: PRINCIPAL_INVESTIGATOR lat: 39.25642 lon: 9.1444 facility: GSK Investigational Site city: Napoli state: Campania zip: 80131 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Giuseppe Spadaro role: PRINCIPAL_INVESTIGATOR lat: 40.85216 lon: 14.26811 facility: GSK Investigational Site city: Roma state: Lazio country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Paolo Palange role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 facility: GSK Investigational Site city: Milano state: Lombardia zip: 20162 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Paolo Tarsia role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: GSK Investigational Site city: Varese state: Lombardia zip: 21100 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Antonio Spanevello role: PRINCIPAL_INVESTIGATOR lat: 45.82058 lon: 8.82511 facility: GSK Investigational Site city: Foggia state: Puglia zip: 71100 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Donato Lacedonia role: PRINCIPAL_INVESTIGATOR lat: 41.45845 lon: 15.55188 facility: GSK Investigational Site city: Padova state: Veneto zip: 35128 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Andrea Vianello role: PRINCIPAL_INVESTIGATOR lat: 45.40797 lon: 11.88586 facility: GSK Investigational Site city: Verona state: Veneto zip: 37134 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Claudio Micheletto role: PRINCIPAL_INVESTIGATOR lat: 45.4299 lon: 10.98444 facility: GSK Investigational Site city: Firenze zip: 50134 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Federico Lavorini role: PRINCIPAL_INVESTIGATOR lat: 43.77925 lon: 11.24626 facility: GSK Investigational Site city: Torino zip: 10128 country: Italy name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Luisa Brussino role: PRINCIPAL_INVESTIGATOR lat: 45.07049 lon: 7.68682 facility: GSK Investigational Site city: Ciudad de Panama zip: 7099 country: Panama name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Reynaldo Chandler role: PRINCIPAL_INVESTIGATOR lat: 8.9936 lon: -79.51973 facility: GSK Investigational Site city: Panama zip: 1001 country: Panama name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Bruno Hammerschlag role: PRINCIPAL_INVESTIGATOR lat: 8.9936 lon: -79.51973 facility: GSK Investigational Site city: Panama zip: 7002 country: Panama name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Lorena Noriega role: PRINCIPAL_INVESTIGATOR lat: 8.9936 lon: -79.51973 facility: GSK Investigational Site city: Panama country: Panama name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Yaricelys Bravo role: PRINCIPAL_INVESTIGATOR lat: 8.9936 lon: -79.51973 facility: GSK Investigational Site city: Bialystok zip: 15-010 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Piotr Siergiejko role: PRINCIPAL_INVESTIGATOR lat: 53.13333 lon: 23.16433 facility: GSK Investigational Site city: Bielsko-Biala zip: 43-300 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Marta Frejowska-Reniecka role: PRINCIPAL_INVESTIGATOR lat: 49.82245 lon: 19.04686 facility: GSK Investigational Site city: Elblag zip: 82-300 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Marek Mital role: PRINCIPAL_INVESTIGATOR lat: 54.1522 lon: 19.40884 facility: GSK Investigational Site city: Katowice zip: 40-083 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Szymon Placzek role: PRINCIPAL_INVESTIGATOR lat: 50.25841 lon: 19.02754 facility: GSK Investigational Site city: Katowice zip: 40-600 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Jakub Kwiatkowski role: PRINCIPAL_INVESTIGATOR lat: 50.25841 lon: 19.02754 facility: GSK Investigational Site city: Ostrowiec Swietokrzyski zip: 27-400 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Anna Olech-Cudzik role: PRINCIPAL_INVESTIGATOR lat: 50.92936 lon: 21.38525 facility: GSK Investigational Site city: Plock zip: 09-407 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Maria Wozniak role: PRINCIPAL_INVESTIGATOR lat: 52.54682 lon: 19.70638 facility: GSK Investigational Site city: Tarnow zip: 33-100 country: Poland name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Bernadetta Majorek-Olechowska role: PRINCIPAL_INVESTIGATOR lat: 50.01381 lon: 20.98698 facility: GSK Investigational Site city: Soham state: Cambridgeshire zip: CB7 5JD country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Anthony Gunstone role: PRINCIPAL_INVESTIGATOR lat: 52.33543 lon: 0.33654 facility: GSK Investigational Site city: Rhyl state: Denbighshire zip: LL18 4HZ country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Selena Harris role: PRINCIPAL_INVESTIGATOR lat: 53.31929 lon: -3.49228 facility: GSK Investigational Site city: Ashton-under-Lyne state: Greater Manchester zip: OL6 6HD country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Omair Razzaq role: PRINCIPAL_INVESTIGATOR lat: 53.48876 lon: -2.0989 facility: GSK Investigational Site city: Corby state: Northamptonshire zip: NN17 2UR country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Amardeep Heer role: PRINCIPAL_INVESTIGATOR lat: 52.49637 lon: -0.68939 facility: GSK Investigational Site city: Guisborough state: South Tees zip: TS14 7DJ country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Teik Goh role: PRINCIPAL_INVESTIGATOR lat: 54.53478 lon: -1.05606 facility: GSK Investigational Site city: Bebington zip: CH63 9JP country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Athanasios Simopoulos role: PRINCIPAL_INVESTIGATOR lat: 53.35 lon: -3.01667 facility: GSK Investigational Site city: Hounslow zip: TW3 3EL country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Ivor Singh role: PRINCIPAL_INVESTIGATOR lat: 51.46839 lon: -0.36092 facility: GSK Investigational Site city: Uttoxeter zip: ST14 5JX country: United Kingdom name: US GSK Clinical Trials Call Center role: CONTACT phone: 877-379-3718 email: GSKClinicalSupportHD@gsk.com name: EU GSK Clinical Trials Call Centre role: CONTACT phone: +44 (0) 20 8990 4466 email: GSKClinicalSupportHD@gsk.com name: Satveer Poonian role: PRINCIPAL_INVESTIGATOR lat: 52.89838 lon: -1.86488 hasResults: False
<|newrecord|> nctId: NCT06261944 id: NIRDM-SXCIP03 briefTitle: A Pivotal Clinical Investigation Confirming the Safety and Accuracy of the Glyconics-DS in Assessment of Glycated Nail Keratin in Individuals With Unknown Diabetes Status and Performance Evaluation of the Glyconics SW Package acronym: ANODE03 overallStatus: RECRUITING date: 2024-03-13 date: 2024-06-30 date: 2024-08-08 date: 2024-02-15 date: 2024-03-21 name: Glyconics Ltd class: INDUSTRY briefSummary: The main clinical study objective is to confirm the accuracy of the Glyconics-DS spectrometer when used in its intended medical purpose population, i.e., in individuals with unknown diabetes risk. Additionally, this investigation will serve as a pivotal performance evaluation for the associated software for correct delivery of the algorithm-based analysis of the individual diabetes risk. The study will be considered positive if the backend delivery of the chemometrics output is performed correctly as per the cloud-based analysis and its delivery represents the essential medical software to be evaluated in this investigation. The 'true' diabetes risk will be contrasted against values of an internal biomarker indicative of glycaemia, HbA1c, as measured based on standardised, certified methodology. conditions: Pre-diabetes conditions: Undiagnosed Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Mass-screening primaryPurpose: SCREENING masking: NONE count: 480 type: ESTIMATED name: Near-infrared (NIR) measure: Dichotomised diabetes risk status measure: Sensitivity and specificity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sant Pau Hospital status: RECRUITING city: Barcelona country: Spain name: Didac Mauricio, MD, PhD role: CONTACT lat: 41.38879 lon: 2.15899 hasResults: False
<|newrecord|> nctId: NCT06261931 id: 6313 briefTitle: Severity Over Time of Early Forms of Spondyloarthritis acronym: STAR overallStatus: NOT_YET_RECRUITING date: 2024-02-12 date: 2026-02-28 date: 2044-02-28 date: 2024-02-15 date: 2024-02-15 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Spondyloarthritis (SpA) is a group of chronic inflammatory pathologies whose progression over time is poorly defined, and in particular the clinical and instrumental elements that can predispose to a condition of disease severity are not completely known. It would be important to have an idea of what the predisposing factors are, possibly already at baseline, and possibly also at follow up, of severe disease, so as to be able to act early with more aggressive and targeted therapies on these patients, so as to achieve remission. conditions: Spondyloarthritis conditions: Spondyloarthritis, Axial studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 387 type: ESTIMATED name: Diagnostic assessment name: Diagnostic assessment measure: spondyloarthritis severity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS city: Roma zip: 00168 country: Italy name: Maria Antonietta D'Agostino role: CONTACT phone: +390630155701 email: mariaantonietta.dagostino@policlinicogemelli.it name: Maria Antonietta D'Agostino role: PRINCIPAL_INVESTIGATOR name: Augusta Ortolan role: SUB_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False
<|newrecord|> nctId: NCT06261918 id: 6269 briefTitle: Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome acronym: PROMETA overallStatus: RECRUITING date: 2024-02-01 date: 2025-02-01 date: 2026-07-01 date: 2024-02-15 date: 2024-02-15 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: This prospective pilot study of biological specimens aims to identify new prognostic and predictive biomarkers of response to standard therapy for local advanced BC, as well as to identify new targets for the development of immuno- therapeutic protocols. First aim is therefore to expand our knowledge to increase the response to preoperative treatment, intensify treatment patterns, and select patients based on clinical parameters. In this regard, it appears imperative to investigate yet under-investigated factors that might impair the response to standard therapy for local advanced BC including association to metabolic syndrome and analysis of tumoral and stromal features supporting a tumor microenvironment impenetrable to both drugs and immune system cells. conditions: Breast Cancer conditions: Metabolic Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Influence of metabolic syndrome on the achievement of pathological complete response measure: Acheivement of pathological complete response measure: Event-free survival (EFS) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli - IRCCS status: RECRUITING city: Roma country: Italy name: Alessandra Fabi role: CONTACT phone: 0630153773 email: alessandra.fabi@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
<|newrecord|> nctId: NCT06261905 id: 2000036908 id: 000 type: OTHER domain: CTGTY briefTitle: Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System overallStatus: RECRUITING date: 2024-03-13 date: 2024-06 date: 2024-06 date: 2024-02-15 date: 2024-04-12 name: Yale University class: OTHER name: University of Pennsylvania briefSummary: The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using \[11C\]-PHNO. The investigators will compare subjects in differences between their own study days and in differences between healthy control subjects and subjects with OUD. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is primarily a within-subject, two scan, randomized, double-blind, placebo-controlled study design. Healthy control subjects will only complete one scan to serve as a baseline comparison for subjects with OUD. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 24 type: ESTIMATED name: [11C]-PHNO name: Calcitriol name: Placebo Control name: PET Scan measure: Non-displaceable Tracer Binding Potentials (BPND) measure: Non-displaceable Tracer Binding Potentials (BPND) measure: Spontaneous Blink Rate (SBR) measure: Continuous Performance Task - Identical Pairs (CPT-IP) measure: Probabilistic Reversal Learning Task (PRLT) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Yale School of Medicine status: RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States name: Marcella Mignosa role: CONTACT phone: 203-903-7795 email: marcella.mignosa@yale.edu name: Adam Stryjewski role: CONTACT phone: 203-535-4424 email: adam.stryjewski@yale.edu name: Marc Potenza, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Gustavo Angarita, MD role: PRINCIPAL_INVESTIGATOR lat: 41.30815 lon: -72.92816 hasResults: False
<|newrecord|> nctId: NCT06261892 id: 2023-002 briefTitle: Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine overallStatus: RECRUITING date: 2023-07-20 date: 2025-06 date: 2025-06 date: 2024-02-15 date: 2024-02-15 name: WomenX Biotech Limited class: INDUSTRY name: Hong Kong Science and Technology Parks Corporation briefSummary: The goal of this clinical trial is
1. To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer.
2. If HPV DNA is not a promising biomarker, other biomarkers will be explored.
3. To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation.
The main question it aims to answer is:
To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
1. Join the briefing session of the study
2. Sign the consent form and health questionnaire
3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
4. Collect the urine sample
If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer conditions: Cervical Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 300 type: ESTIMATED name: Collect HPV DNA from urine measure: HPV DNA from urine is a promising biomarkers for the detection of pre-cervical/ cervical cancer sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: WomenX Biotech Limited status: RECRUITING city: Hong Kong country: Hong Kong name: Alan LIU, Master role: CONTACT phone: +852 64786939 email: alanliu@womenx.net lat: 22.27832 lon: 114.17469 hasResults: False
<|newrecord|> nctId: NCT06261879 id: 2023-001 briefTitle: Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood overallStatus: RECRUITING date: 2023-07-20 date: 2025-06 date: 2025-06 date: 2024-02-15 date: 2024-02-15 name: WomenX Biotech Limited class: INDUSTRY briefSummary: The goal of this clinical trial is
1. To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical or/and cervical cancer.
2. If ACTN4 is not a promising biomarker, other biomarkers will be explored.
3. To develop an effective and non-invasive detection method for pre-cervical or/and cervical cancer.
in Women with menstruation.
The main question it aims to answer is:
To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
1. Join the briefing session of the study
2. Sign the consent form and health questionnaire
3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
4. Collect the menstrual blood sample
If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer conditions: Cervical Cancer conditions: CIN studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 300 type: ESTIMATED name: Special sanitary pad measure: ACTN4 is a promising biomarkers for the detection of pre-cervical/ cervical cancer sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: WomenX Biotech Limited status: RECRUITING city: Hong Kong country: Hong Kong name: Alan LIU, Master role: CONTACT phone: +852 64786939 email: alanliu@womenx.net lat: 22.27832 lon: 114.17469 hasResults: False
<|newrecord|> nctId: NCT06261866 id: MultiInter-CCS briefTitle: Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome acronym: MultiInter-CCS overallStatus: RECRUITING date: 2011-04-07 date: 2024-12-31 date: 2028-12-31 date: 2024-02-15 date: 2024-02-15 name: Medical University of Warsaw class: OTHER briefSummary: The aim of this prospective, investigator-initiated study is to evaluate the diagnostic accuracy and correlations between functional indices (fractional flow reserve, FFR) and morphometric indices: luminal and qualitative parameters assessed by optical coherence tomography (OCT) including minimal lumen area, plaque type, presence of thin cap fibroatheroma among patients with chronic coronary syndrome identified with intermediate grade coronary stenosis. conditions: Chronic Coronary Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Correlation between fractional flow reserve (FFR) and minimal lumen area within the coronary stenosis measure: Correlation between fractional flow reserve (FFR) and mean lumen area within the coronary stenosis measure: Major adverse cardiovascular events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Warsaw status: RECRUITING city: Warsaw country: Poland name: Mariusz Tomaniak, MD, PhD, Assoc. Prof. role: CONTACT email: mariusz.tomaniak@wum.edu.pl name: Piotr Baruś, MD role: CONTACT email: piotr.barus@wum.edu.pl lat: 52.22977 lon: 21.01178 hasResults: False
<|newrecord|> nctId: NCT06261853 id: 2-081-23 briefTitle: The Impact of 3D-CBCT Imaging on Nerve Injuries During Wisdom Tooth Surgery acronym: IMPACTION overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-05 date: 2025-05 date: 2024-02-15 date: 2024-02-28 name: University of Aberdeen class: OTHER name: Zarqa University name: King's College London briefSummary: The investigators aim to investigate if the additional information available from a 3D scan of the wisdom tooth can reduce the risk of nerve injury during wisdom tooth surgery compared to conventional 2D images.
Wisdom tooth surgery is a common surgical procedures that a significant proportion of the population will undergo. As with any other surgical procedure, there are potential complications, of which, injury to the nerve supplying feeling to the lip, chin, and tongue is the most significant. This can lead to persistent pain, tingling, or numbness that may impact a patient's ability to eat and function.
The risk of nerve injury during wisdom tooth surgery is assessed using X-ray images, which show the position of the nerve and tooth in the jawbone. 2D and 3D scans are used, which have their own advantages and disadvantages such as reduced cost and radiation dose with 2D or more information from 3D images, but it remains unclear which is better at reducing the risk of nerve injuries. conditions: Inferior Alveolar Nerve Injuries conditions: Impacted Third Molar Tooth studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Pragmatic, two-arm, single-blinded, randomised controlled trial designed to investigate the differences between 3D cone-beam computerised tomography (CBCT) and 2D orthopantomography (OPG) in reducing inferior alveolar nerve injuries during wisdom tooth surgery. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Double (Participant, Outcomes Assessor) A single-blinded methodology will be employed due to the nature of the image-based investigation where the surgeon is required to utilise one imaging modality during the surgery. In order to eliminate any influence or bias on the outcomes and data obtained for the primary objective, both the subject (patient) and the study member who will do the follow-up call will be blinded to the imaging techniques used on the day of surgery. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 1292 type: ESTIMATED name: 3D-CBCT name: 2D-OPG measure: The number of patients reporting altered sensation in their lip and/or chin on the side of wisdom tooth surgery measure: Surgical time measure: Planned surgical approach measure: Intraoperative complications measure: Postoperative Complications measure: Wisdom tooth impaction classification sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: King'S College Hospital Nhs Foundation Trust city: London state: England zip: SE5 9RS country: United Kingdom name: Nadine Khawaja, BDS PhD role: CONTACT email: nadine.khawaja@kcl.ac.uk name: Nadine Khawaja role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Aberdeen Dental Hospital city: Aberdeen state: Scotland zip: AB25 2ZR country: United Kingdom name: Anand Lalli, BDS PhD role: CONTACT phone: 01224553515 email: anand.lalli@nhs.scot name: Rahmeh Alhyari, BDS role: CONTACT email: r.alhyari.22@abdn.ac.uk name: Anand Lalli, Consultant in Oral Surgery role: PRINCIPAL_INVESTIGATOR lat: 57.14369 lon: -2.09814 hasResults: False
<|newrecord|> nctId: NCT06261840 id: 2024-101 briefTitle: Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2029-05-01 date: 2029-07-31 date: 2024-02-15 date: 2024-02-15 name: Tulane University class: OTHER name: University of Alabama at Birmingham name: Louisiana State University Health Sciences Center in New Orleans briefSummary: This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men. conditions: Trichomonas Vaginitis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1200 type: ESTIMATED name: Metronidazole 500 mg name: Secnidazole 2000 MG measure: Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06261827 id: RECORD briefTitle: High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB overallStatus: RECRUITING date: 2024-02-20 date: 2025-02-20 date: 2025-04-01 date: 2024-02-15 date: 2024-03-07 name: Tomsk National Research Medical Center of the Russian Academy of Sciences class: OTHER briefSummary: The primary aim of this single-center, prospective, randomized, controlled, study is to test the hypothesis that inhalation of NO 200 ppm prevents the development of nosocomial pneumonia in patients at risk after cardiac surgery under CPB. The study is interventional. Examination and treatment of patients is carried out in accordance with the approved standards of medical care for the relevant diseases. During the study, no experimental or unregistered (not approved for use) medical or diagnostic procedures in the territory of the Russian Federation will be carried out. The study includes patients admitted to the Cardiac Surgery Department of Cardiology Research Institute of Tomsk National Research Medical Center for elective surgery with CPB. conditions: Nosocomial Pneumonia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 160 type: ESTIMATED name: Sham treatment name: 200-ppm NO measure: Incidence of nosocomial pneumonia (percent) measure: Total leukocyte counts (10*9/L) measure: Immature cell counts (percentage) measure: C-reactive protein (CRP) level (mg/L) measure: PCT (procalcitonin) test (ng/mL) measure: Presepsin levels (pg/mL) measure: Ferritin levels (ng/mL) measure: LDH (lactate dehydrogenase) levels (IU/L) measure: Interleukin-6 (IL-6) levels (pg/mL) measure: Interleukin-8 (IL-8) levels (pg/mL) measure: Surfactant protein SP-D plasma levels (ng/mL) measure: sRAGE levels (pg/mL) measure: endothelin-1 levels (pg/mL) measure: Asymmetric dimethylarginine (ADMA) levels (ng/mL) measure: Vascular endothelial growth factor A (VEGF-A) levels (pg/mL) measure: Angiopoietin-1 levels (ng/mL) measure: Angiopoietin-2 levels (ng/mL) measure: S/F index (ratio) measure: Incidence of adverse lung ultrasound findings (percentage) measure: Six-minute walk test (6MWT) distance (meters) measure: Lung vital capacity (L) measure: Forced vital capacity (L) measure: Forced expiratory volume (L/s) measure: Peak expiratory flow (L/s) measure: VE-minute ventilation (L/min) measure: VT-tidal volume (L) measure: VE/VO2 - ventilatory equivalents for oxygen (ratio) measure: VE/VСO2 - ventilatory equivalent for carbon dioxide measure: PetO2 - partial pressure of oxygen in exhaled air (mm Hg) measure: PetCO2 - partial pressure of carbon dioxide in exhaled air (mmHg) measure: Exhaled NO levels (ppm) measure: Systolic blood pressure (SBP) levels (mmHg) measure: Diastolic blood pressure (DBP) levels (mmHg) measure: Heart rate (HR) (bpm) measure: Respiratory rate (RR) (brpm) measure: Saturation of peripheral oxygen (SpO2) levels (percentage) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cardiology Research Institute Tomsk national Research Medical Center status: RECRUITING city: Tomsk country: Russian Federation name: Nikolay O. Kamenshchikov role: CONTACT phone: +79138183657 email: nikolajkamenof@mail.ru name: Tatiana P Kalashnikova role: CONTACT phone: +79138141664 email: kalashnikova-t@mail.ru lat: 56.49771 lon: 84.97437 hasResults: False
<|newrecord|> nctId: NCT06261814 id: iRISID-2023-2142 briefTitle: Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2027-07-01 date: 2028-01-01 date: 2024-02-15 date: 2024-04-01 name: john eisenbrey class: OTHER briefSummary: This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods. conditions: Liver Neoplasms studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: No Data Available primaryPurpose: DIAGNOSTIC masking: NONE count: 266 type: ESTIMATED name: Sulfur Hexafluoride Lipid Microspheres name: Contrast-Enhanced Ultrasound name: Transarterial Chemoembolization name: Medical Chart Review measure: Recurrence measure: Specificity measure: Positive predictive value measure: Negative predictive value measure: False discovery rate measure: Residual tumor vacularity measure: Diagnostic performance for each imaging mode measure: Ability of the model to predict binary treatment response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sidney Kimmel Cancer Center at Thomas Jefferson University city: Philadelphia state: Pennsylvania zip: 19107 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
<|newrecord|> nctId: NCT06261801 id: GZY-ZJ-KJ-23088 briefTitle: Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol overallStatus: RECRUITING date: 2024-02-07 date: 2025-07-20 date: 2025-12-20 date: 2024-02-15 date: 2024-02-15 name: The Third People's Hospital of Hangzhou class: OTHER name: The Third Affiliated hospital of Zhejiang Chinese Medical University briefSummary: Trigeminal herpetic neuralgia is a common type of Zoster-associated Pain (ZAP), which troubles individuals in all ages and burdens society all over the world. Eleactroaupuncture (EA) is increasingly used in the treatment of ZAP due to its advantages such as low price, high safety, no adverse reactions, and high patient acceptance. Therefore, it is necessary to conduct randomized controlled trials to evaluate the effectiveness and safety of EA on ZAP and whether EA can be used as a substitute for pregabalin. conditions: Trigeminal Herpetic Neuralgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Medication Group name: EA Group name: EA+Medication Group measure: Visual Analog Score change measure: McGill Pain Questionnaire Short Form (SF-MPQ) measure: Brief Pain Inventory Scale (BPI-SF) measure: Medical Outcomes Study Sleep Scale (MOS-SS) measure: Hamilton Depression Rating Scale (HAMD)Hamilton Anxiety Rating Scale (HAMA) measure: Hamilton Depression Rating Scale (HAMD) measure: Short Form 36 Health Survey (SF-36) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Hangzhou Third People's Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310009 country: China name: Pin Lin role: CONTACT phone: 1358876268686 email: yjlp1@163.com name: Chengcheng Kong role: CONTACT phone: 8613868078286 lat: 30.29365 lon: 120.16142 hasResults: False
<|newrecord|> nctId: NCT06261788 id: EASY II Trial briefTitle: Efficacy and Safety of the Sync-AV II Temporary Cardiac Pacing Catheter overallStatus: COMPLETED date: 2023-06-01 date: 2023-09-13 date: 2023-09-26 date: 2024-02-15 date: 2024-02-15 name: Swift Sync, Inc. class: INDUSTRY name: Regulatory and Quality Solutions briefSummary: This is a prospective, single-center, non-randomized open label study. The objective of this study is to evaluate the efficacy and safety of the Sync-AV II Temporary Cardiac Pacing Catheter in subjects whose elective surgical or interventional procedure require temporary pacing support. conditions: Heart Block conditions: Valve Heart Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ACTUAL name: Temporary pacing measure: With a commercially available pacing box and/or analyzer, measure the ventricular pacing threshold at 24 hours post implant of the investigational device (index procedure) measure: Procedure related complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centro de Intervenciones Endovasculares y Cirugia Cardiovascular city: Asunción country: Paraguay lat: -25.30066 lon: -57.63591 hasResults: False
<|newrecord|> nctId: NCT06261775 id: IRB-2401011-EXM briefTitle: Effect of Minimally Processed Animal Protein on Biomarkers for Cognitive Decline overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-30 date: 2024-02-07 date: 2026-01-02 date: 2024-02-15 date: 2024-02-22 name: South Dakota State University class: OTHER briefSummary: Minimally processed animal protein is a premier source of essential macro and micronutrients in the diet and is important, especially to older adults who are at increased risk of nutritional deficiency and age-related physiological changes. Our central hypothesis is that adding lean animal protein within a dietary guideline-based diet will enhance nutrient adequacy and attenuate markers of cognitive decline. This is a retrospective study leveraging samples collected from the feeding trial NCT05581953. PI for both studies are the same. conditions: Healthy Lifestyle studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 36 type: ACTUAL name: Red meat-based meal name: Lacto-ovo-vegetarian meal measure: Concentration of phosphatidylcholine in blood sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: South Dakota State University, Wagner Hall 416 city: Brookings state: South Dakota zip: 57007 country: United States lat: 44.31136 lon: -96.79839 hasResults: False
<|newrecord|> nctId: NCT06261762 id: SDC-24-1 briefTitle: Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic Zone overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2026-06-30 date: 2026-06-30 date: 2024-02-15 date: 2024-02-15 name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University class: OTHER briefSummary: The goal of this observational study is to evaluate the post-extraction hard and soft tissue dimension changes in patients requiring consecutive extractions and unassisted socket healing in the anterior maxilla. The main questions it aims to answer are:
* Is significant alveolar ridge resorption observed at center sites after consecutive extractions
* Is significant alveolar ridge resorption observed at the interalveolar septum after consecutive extractions, are different extraction sites associated with significantly different bone resorption
* Is a thick or thin wall phenotype associated with the amount of bone resorption
* Is soft tissue thickness change associated with the corresponding location (extraction site or interalveolar septum) and post-extraction thickness of the bone
* Is the interdental papilla height significantly affected after extractions.
Participants will undergo consecutive (two) extractions and will be evaluated after subsequent unassisted socket healing for 8 weeks. conditions: Wound Heal studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED measure: Bone level change from baseline measure: Soft tissue change from baseline measure: Correlation between baseline facial bone thickness and dimensional soft tissue alterations during healing at the interalveolar septum. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06261749 id: EmgSCAPULA briefTitle: Analysis of Scapular Musculature Activation During Targeted Abdominal Contraction With Scapular Stabilization Exercises overallStatus: RECRUITING date: 2024-02-15 date: 2024-04 date: 2024-08 date: 2024-02-15 date: 2024-02-28 name: Hacettepe University class: OTHER briefSummary: Muscle activation of the upper trapezius, lower trapezius and serratus anterior muscles will be measured during prone scapular retraction exercises. Then the same exercises will be performed with abdominal contraction using a stabilizer and muscle activity of the same muscles will be measured. A comparison will be made between the two conditions. conditions: Scapula; Increased studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Voluntary Abdominal Contractions name: Exercise measure: Electromyography sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Hacettepe University status: RECRUITING city: Ankara zip: 06100 country: Turkey name: İrem Düzgün, Prof role: CONTACT phone: +903051577 email: iremduzgun@yahoo.com lat: 39.91987 lon: 32.85427 hasResults: False
<|newrecord|> nctId: NCT06261736 id: 2107044-1 briefTitle: The Effectiveness of Prophylactic Antibiotics for Urethral Bulking overallStatus: RECRUITING date: 2023-10-24 date: 2025-05 date: 2025-05 date: 2024-02-15 date: 2024-02-15 name: Atlantic Health System class: OTHER briefSummary: The goal of this clinical trial is to evaluate if prophylactic antibiotics in urethral bulking are effective in reducing postprocedural urinary tract infections. conditions: Stress Urinary Incontinence conditions: Postoperative Urinary Tract Infection conditions: Urethral Bulking studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 70 type: ESTIMATED name: Prophylactic antibiotics name: No antibiotics measure: Rate of urinary tract infection (UTI) measure: Rate of postoperative urinary retention measure: Rates of other postoperative complications sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Atlantic Health status: RECRUITING city: Morristown state: New Jersey zip: 07960 country: United States name: Tess Gao, MD role: CONTACT phone: 973-971-7267 email: tess.gao@atlantichealth.org name: Erika Wasenda, MD role: PRINCIPAL_INVESTIGATOR lat: 40.79677 lon: -74.48154 hasResults: False
<|newrecord|> nctId: NCT06261723 id: PI22/1009 briefTitle: Effect of Non-chirurgical Periodontal Treatment on the Immune System From a Gender Perspective overallStatus: RECRUITING date: 2024-02-15 date: 2025-09-01 date: 2025-12-31 date: 2024-02-15 date: 2024-04-16 name: Milagros Rocha Barajas class: OTHER name: Instituto de Salud Carlos III briefSummary: The goal of this observational study is to evaluate non-surgical periodontal treatment in women and men with periodontitis with and without obesity. The main questions it aims to answer are:
* If non-surgical periodontal treatment of patients with chronic periodontitis can modulate the innate and adaptive immune response taking into account patient gender and the coexistence of obesity
* If there are specific miRNAs that can regulate this immune response and can be considered as suitable biomarkers and therapeutic targets.
Obese or non-obese participants with periodontitis will receive non-surgical periodontal treatment, consisting of oral health guidance and mechanical periodontal debridement throughout the mouth using an ultrasonic device and manual curettes. Researchers will compare four groups: obese women, non-obese women, obese men, and non-obese men, to clarify the involment of immune response after treatment, considering the coexistence of obesity and potential gender differences. conditions: Periodontal Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: non-chirurgical periodontal treatment measure: Changes in inflammasome complex activation grade in patients with chronic periodontitis with and without obesity, before and after non-surgical periodontal treatment. measure: Changes in endothelial function in the study population. measure: Changes in endothelial function at molecular level in the study population. measure: Changes in the systemic inflammation status in the study population. measure: Changes in the expression of genes related to inflammatory pathways in PBMC in the study population. measure: Changes in the expression of genes related to oxidative stress levels in PBMC in the study population. measure: Changes in the expression of genes related to cellular respiration in PBMC in the study population. measure: Sequence miRNAs in biological fluids in patients with chronic periodontitis with and without obesity, before and after non-surgical periodontal treatment. measure: Evaluate the distribution and phenotype of different T lymphocyte and monocyte subpopulations in the study population. measure: Changes in the protein expression of autophagy markers in PBMC in the study population. measure: Evaluate autophagy flux in the study population. measure: Evaluate autophagosome formation in the study population. sex: ALL minimumAge: 18 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Dr Peset status: RECRUITING city: Valencia zip: 46017 country: Spain name: Milagros Rocha Barajas, PhD role: CONTACT phone: 0034 963 189 132 email: milagros.rocha@fisabio.es name: Milagros Rocha Barajas, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.46975 lon: -0.37739 facility: University Hospital Dr. Peset status: RECRUITING city: Valencia zip: 46017 country: Spain name: Milagros Rocha Barajas role: CONTACT phone: 963188875 email: milagros.rocha@fisabio.es lat: 39.46975 lon: -0.37739 hasResults: False
<|newrecord|> nctId: NCT06261710 id: EA2_253_23 briefTitle: Intrapartum Ultrasound in Labor: Sonography Only, Few Internal Examinations acronym: SOFIE overallStatus: RECRUITING date: 2024-02-27 date: 2029-02-01 date: 2030-02-01 date: 2024-02-15 date: 2024-02-16 name: Larry Hinkson class: OTHER briefSummary: This is a prospective, randomized trial to determine whether the use of sonographic parameters during labor results in less intrapartum infection compared to traditional invasive examination. Other secondary outcomes include maternal satisfaction and overall birth outcomes. conditions: Labor Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 356 type: ESTIMATED name: Sonography in labour measure: Maternal Fever Incidence measure: Maternal Tachycardia Incidence measure: Maternal Leucocytosis measure: Uterine tenderness measure: Fetal Tachycardia measure: Foul-smelling amniotic fluid measure: Average age measure: Maternal weight measure: Maternal height measure: Completed weeks of pregnancy measure: Previous pregnancy measure: Incidence of Vaginal Examinations measure: Incidence of Caesarean section measure: Incidence of Instrumental Delivery measure: Incidence of estimated blood loss >1000 ml measure: Incidence of antibiotics usage measure: Incidence of Neonatal Admission measure: Neonatal weight measure: Maternal Satisfaction Scores measure: Incidence of Chorioamnionitis on Placenta Histologie sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Charité University Hospital status: RECRUITING city: Berlin country: Germany name: Larry Hinkson, FRCOG role: CONTACT lat: 52.52437 lon: 13.41053 hasResults: False
<|newrecord|> nctId: NCT06261697 id: P.T.REC/012/004876 briefTitle: Relationship Between Smartphone Addiction and Temporomandibular Joint Disorders Among Adults in Egypt. overallStatus: NOT_YET_RECRUITING date: 2024-02-20 date: 2024-04 date: 2024-06 date: 2024-02-15 date: 2024-02-21 name: Cairo University class: OTHER briefSummary: Cross sectional study to investigate the relation between Smartphone addiction and temporomandibular disorders among youth population in Egypt. An online- based questionnaire study. A 296 participants who are Egyptians with age between18 and 35 years old without prior neck and upper extremity related diseases, orofacial trauma or surgeries, history of rheumatoid arthritis or congenital musculoskeletal problems. An online- based questionnaire will be sent through different social media platforms, it will include three screens, the first includes the consent form, the second includes the demographic data (year of birth, current educational status, gender and geographic information ), and the third page includes questionnaires
. conditions: Temporomandibular Disorders conditions: Smartphone Addiction studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 296 type: ESTIMATED name: A web based survey measure: Fonseca Anamnestic Index (FAI) questionnaire measure: Smartphone Addiction Scale-Short version (SAS-SV) questionnaire measure: Patient Health Questionnaire (PHQ) sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06261684 id: MS-259-2023 briefTitle: Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial. overallStatus: RECRUITING date: 2023-10-01 date: 2024-10-01 date: 2024-10-01 date: 2024-02-15 date: 2024-02-15 name: Cairo University class: OTHER briefSummary: The goal of this prospective randomized controlled study is to study the safety and efficacy of intralesional acyclovir compared to cryotherapy in plantar warts. The main questions needed to be answered are:
1. Is Intralesional acyclovir safe for plantar warts?
2. Is Intralesional acyclovir more efficient in treating plantar warts compared to cryotherapy? conditions: Plantar Wart studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 92 type: ESTIMATED name: Intralesional Acyclovir name: Cryotherapy measure: Cure rate measure: Recurrence rate measure: Patient satisfaction score measure: Correlation of treatment with number of ipsilateral warts measure: Correlation of treatment with age measure: Correlation of treatment with gender measure: Correlation of treatment with size of the wart sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo University Hospital status: RECRUITING city: Cairo country: Egypt name: Basant Helal, MRCP role: CONTACT name: Shahira Ramadan, Professor role: PRINCIPAL_INVESTIGATOR name: Yousra Azzazi, Lecturer role: SUB_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
<|newrecord|> nctId: NCT06261671 id: 2312-ABU-028-VF briefTitle: Effect of Antioxydant-enriched Media on Blastocyst Euploidy Rates. acronym: GX overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: ART Fertility Clinics LLC class: OTHER briefSummary: One of the most sensible factors in IVF culture conditions is the susceptibility of gametes and embryos to an induced increase in reactive oxidative species (ROS) caused by the artificial environment. This study aims to evaluate the impact of using antioxidant-supplemented media during culture to evaluate embryo ploidy rates in a prospective randomized trial using sibling oocytes. conditions: Infertility conditions: In Vitro Fertilization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomization list (indicating Gx Media Vitrolife or GT Coopersurgical) will be used to verify to which group the first half of oocytes will be allocated to. In case an odd number of oocytes is present, one extra oocyte is allocated to the group as indicated by the randomization list. primaryPurpose: TREATMENT masking: NONE count: 500 type: ESTIMATED name: antioxidants-enriched culture medium (Gx) measure: Blastocyst ploidy is determined after a biopsy of trophectoderm cells, taken from the blastocyst on day 5, 6 or 7 from development. The following outcomes are possible: • Normal • Abnormal • No result/Inconclusive • Low or high Mosaic measure: Cycle ploidy rate: the number of euploid embryos in the group Blastocyst quality at the time of biopsy based on modified Gardner's criteria. Usable blastocyst rate per group and per day of biopsy (day 5, 6, 7) sex: ALL minimumAge: 18 Years maximumAge: 43 Years stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06261658 id: TESOVA2022 briefTitle: Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma acronym: TESOVA2022 overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-29 date: 2033-12-29 date: 2024-02-15 date: 2024-02-15 name: IRCCS Azienda Ospedaliero-Universitaria di Bologna class: OTHER briefSummary: The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue. conditions: Cryopreservation conditions: Ovary Injury conditions: Infertility, Female conditions: Menopause Ovarian Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Cryopreserved Ovarian Tissue Reimplantation measure: Safety of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma measure: Effectiveness of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Diego Raimondo status: RECRUITING city: Bologna state: BO zip: 40138 country: Italy name: Diego Raimondo, MD role: CONTACT phone: 0512144389 phoneExt: 0039 email: die.raimondo@gmail.com name: Renato Seracchioli, MD role: PRINCIPAL_INVESTIGATOR name: Diego Raimondo, MD role: SUB_INVESTIGATOR name: Rossella Vicenti, PhD role: SUB_INVESTIGATOR name: Valentina Magnani, PhD role: SUB_INVESTIGATOR lat: 44.49381 lon: 11.33875 hasResults: False